ARVINAS, INC. Increase (Decrease) in Accounts Payable
ARVINAS, INC. (ARVN) reported Increase (Decrease) in Accounts Payable of -$22.60 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2022-05-05
- ARVINAS, INC. increase (decrease) in accounts payable for the quarter ending 2022-03-31 was -$22.60M, a 1355.56% decline year-over-year.
- ARVINAS, INC. increase (decrease) in accounts payable for the quarter ending 2021-12-31 was $26.23M, a 1067.29% increase year-over-year.
- ARVINAS, INC. increase (decrease) in accounts payable for the quarter ending 2021-09-30 was -$82.86K, a 104.08% decline year-over-year.
- ARVINAS, INC. increase (decrease) in accounts payable for the quarter ending 2021-06-30 was -$4.24M.
- ARVINAS, INC. increase (decrease) in accounts payable for fiscal 2021 was $23.70M, a 1085.00% increase from fiscal 2020.
- ARVINAS, INC. increase (decrease) in accounts payable for fiscal 2020 was $2.00M, a 33.33% increase from fiscal 2019.
- ARVINAS, INC. increase (decrease) in accounts payable for fiscal 2019 was $1.50M, a 25.08% decline from fiscal 2018.
- ARVINAS, INC. increase (decrease) in accounts payable for fiscal 2018 was $2.00M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-03-31 | -$22.60M 10-Q · filed 2022-05-05 | $3.63M derived: sum of 2 quarters · filed 2022-05-05 | $3.54M derived: sum of 3 quarters · filed 2022-05-05 | -$700.00K derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-12-31 | $26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $26.14M derived: sum of 2 quarters · filed 2022-02-28 | $21.90M derived: sum of 3 quarters · filed 2022-02-28 | $23.70M 10-K · filed 2022-02-28 | ||
| 2021-09-30 | -$82.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$4.33M derived: sum of 2 quarters · filed 2021-11-03 | -$2.53M 10-Q · filed 2021-11-03 | -$279.07K derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-06-30 | -$4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$2.44M 10-Q · filed 2021-08-05 | -$196.21K derived: sum of 3 quarters · filed 2022-05-05 | $1.84M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-03-31 | $1.80M 10-Q · filed 2022-05-05 | $1.77M 10-Q · filed 2021-05-04 | $4.05M derived: sum of 2 quarters · filed 2022-05-05 | $6.08M derived: sum of 3 quarters · filed 2022-05-05 | $5.71M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.28M derived: sum of 2 quarters · filed 2022-02-28 | $3.91M derived: sum of 3 quarters · filed 2022-02-28 | $2.00M 10-K · filed 2022-02-28 | $2.04M 10-K · filed 2021-03-01 | |
| 2020-09-30 | $2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.66M derived: sum of 2 quarters · filed 2021-11-03 | -$246.73K 10-Q · filed 2021-11-03 | $1.87M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | -$367.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$2.28M 10-Q · filed 2021-08-05 | -$160.59K derived: sum of 3 quarters · filed 2022-02-28 | $639.91K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$1.91M 10-Q · filed 2021-05-04 | $207.32K derived: sum of 2 quarters · filed 2022-02-28 | $1.01M derived: sum of 3 quarters · filed 2022-02-28 | $1.29M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.92M derived: sum of 2 quarters · filed 2022-02-28 | $3.20M derived: sum of 3 quarters · filed 2022-02-28 | $1.50M 10-K · filed 2022-02-28 | $1.61M 10-K · filed 2020-03-16 | |
| 2019-09-30 | $800.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.09M derived: sum of 2 quarters · filed 2020-11-05 | -$618.96K 10-Q · filed 2020-11-05 | $678.97K derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $284.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$1.42M 10-Q · filed 2020-08-04 | -$121.53K derived: sum of 3 quarters · filed 2021-03-01 | -$477.35K derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | -$1.70M 10-Q · filed 2020-04-28 | -$406.31K derived: sum of 2 quarters · filed 2021-03-01 | -$762.13K derived: sum of 3 quarters · filed 2021-03-01 | -$1.07M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $942.11K derived: sum of 2 quarters · filed 2021-03-01 | $631.96K derived: sum of 3 quarters · filed 2021-03-01 | $2.00M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | -$355.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$665.97K derived: sum of 2 quarters · filed 2019-11-04 | $704.23K 10-Q · filed 2019-11-04 | $382.78K derived: sum of 4 quarters · filed 2019-11-04 | ||
| 2018-06-30 | -$310.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $1.06M 10-Q · filed 2019-08-05 | $738.60K derived: sum of 3 quarters · filed 2019-08-05 | |||
| 2018-03-31 | $1.37M 10-Q · filed 2019-05-09 | $1.05M derived: sum of 2 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | -$321.45K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$969.48K 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | -$648.03K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |